4'-[4-[[[(1R)-1-(2-氯苯基)乙氧基]羰基]氨基]-3-甲基-5-异恶唑基]-联苯-4-乙酸

AM966 (订货以英文为准)

编号:A125594
CAS号:1228690-19-4
分子式:C27H23CLN2O5
分子量:490.93
货号 品牌 包装 目录价 您的价格 库存 数量 购买
A125594-50mg 阿拉丁 50mg ¥4119.90
A125594-10mg 阿拉丁 10mg ¥997.90
A125594-5mg 阿拉丁 5mg ¥677.90
产品名称 AM966
中文名称 4'-[4-[[[(1R)-1-(2-氯苯基)乙氧基]羰基]氨基]-3-甲基-5-异恶唑基]-联苯-4-乙酸
CAS号 1228690-19-4
分子式(M.F.) C27H23CLN2O5
分子量(M.W.) 490.93
储存条件 -20°C储存
溶解性DMSO
存贮条件储存温度-20°C
产品介绍AM966是高亲和性的口服的溶血磷脂酸(LPA1)受体拮抗剂,IC50为17 nM,比对其它LPA受体的抑制性高。
生化机理AM966 is a high affinity, selective, oral LPA1 (lysophosphatidic acid receptor) antagonist, with selectivity for this receptor over the other LPA receptors. In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC(50)= 17 nM) from Chinese hamster ovary cells stably expressing human LPA(1) receptors and inhibited LPA-induced chemotaxis (IC(50)= 181 nM) of human IMR-90 lung fibroblasts expressing LPA(1) receptors. AM966 demonstrated a good pharmacokinetic profile following oral dosing in mice. In the mouse, AM966 reduced lung injury, vascular leakage, inflammation and fibrosis at multiple time points following intratracheal bleomycin instillation. AM966 also decreased lactate dehydrogenase activity and tissue inhibitor of metalloproteinase-1, transforming growth factor beta1, hyaluronan and matrix metalloproteinase-7, in bronchoalveolar lavage fluid. Anti-inflammatory agents.
别名4'-(4-((((1R)-1-(2-氯苯基)乙氧基)羰基)氨基)-3-甲基-5-异恶唑基)-联苯-4-乙酸;;AM 966;AM-966; 4'-(4-((((1r)-1-(2-chlorophenyl)ethoxy)carbonyl)amino)-3-methyl-5-isoxazolyl)-(1,1'-biphenyl)-4-acetic acid;
WGK德国3
搜索质检报告(COA)
搜索MSDS
相关产品
CAS号:7704-98-5
¥ 419.00 T819979-100g
CAS号:7758-02-3
¥ 223.00 P816703-25g
CAS号:288-32-4
¥ 60.00 I811843-25g
CAS号:7791-20-0
¥ 899.00 N814991-5g
CAS号:71-41-0
¥ 115.00 P815993-500ml
CAS号:108-46-3
¥ 225.00 R817303-100g
CAS号:1499-10-1
¥ 556.00 D807000-250mg
CAS号:98-88-4
¥ 258.00 B802234-500g
CAS号:9002-92-0
¥ 520.00 767315-5g